Protocol Ledger

NCT04223856 · Phase III · ACTIVE NOT RECRUITING

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Interventional Phase III clinical trial protocol NCT04223856 sponsored by Astellas Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-03-30 Enrollment: 886 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04223856
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)886 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04223856
Protocol FieldVerified Registry Value
NCT IdentifierNCT04223856
Consolidated Lead SponsorAstellas Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment886 participants (ACTUAL)
Registered Start Date2020-03-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI